CEDARS-SINAI MEDICAL CENTER

The 55th RANZCO Congress in Adelaide, 1-4 November 2024, features a dynamic speaker lineup addressing eye transplant feasibility, uveitis insights, and sustainability. Early registrations are up 10% from last year, promising a vibrant event. Key speakers include Prof. Justine Smith on uveitis, Prof. Robyn Jamieson on precision medicine, and Prof. Jeffrey Goldberg on eye transplantation. The congress emphasizes sustainability and offers both in-person and online experiences.

September 2024 saw FDA approval of guselkumab (Tremfya) for ulcerative colitis and a CRL for Vanda Pharmaceuticals’ tradipitant for gastroparesis. Research highlighted treatment dissatisfaction in IBS patients, key bacteria affecting IBD response to thiamine, and FMT delivery methods for IBS. Upper GI mucosal damage was linked to Parkinson disease risk, while MASLD and MetALD increased liver and gastrointestinal cancer risks. The 2024 GHAPP conference featured discussions on medication positioning in Crohn disease and managing gut-brain interaction disorders.

Recent clinical readouts on small molecules targeting BTK for MS, Axl, TYRO3, Mer for oncology, HIF prolyl-hydroxylase in anemia, ET/AT in nephrology, JAK2 inhibitor for myelofibrosis, and THR-beta in NASH.

Recent clinical readouts and news on small molecules targeting BTK for MS, Axl, TYRO3, Mer for oncology, HIF prolyl-hydroxylase in anemia, ET/AT in nephrology, a JAK2 inhibitor for myelofibrosis, and THR-beta in NASH.

CSL and Arcturus Therapeutics received approval from Japan's MHLW for their updated sa-mRNA Covid-19 vaccine, Kostaive, targeting the JN.1 Omicron subvariants for adults 18 and older. Meiji Seika Pharma will distribute the vaccine in time for the October Covid-19 vaccination campaign, marking the world's first commercially available sa-mRNA Covid-19 vaccine for adults. The approval is based on clinical evidence supporting the vaccine's safety and effectiveness, with data showing superior immunogenicity to Omicron BA 4/5 and duration of immunity up to one year.

Recent FDA approval of guselkumab (Tremfya) for UC and other advancements in IBD treatment offer more options, prompting reevaluation of CD and UC management. Andrea Banty, NP, DNP, emphasizes the importance of aligning patient goals with treatment options, considering administration preferences and safety risks.

Recent clinical readouts and news on small molecules targeting BTK for MS, Axl, TYRO3, Mer in oncology, HIF prolyl-hydroxylase in anemia, ET/AT in nephrology, JAK2 inhibitor for myelofibrosis, and THR-beta in NASH.

An overgrowth of gut archaea producing methane may cause severe constipation in people with intestinal methanogen overgrowth (IMO). People with IMO are twice as likely to have constipation and less likely to have diarrhea. IMO can be detected through a breath test, and treatment involves antibiotics and a specialized diet to boost healthy gut microbes.

Cedars-Sinai Medical Center in LA added to Edelife Clinical Trial for XLHED, offering prenatal treatment for boys affected by x-linked hypohidrotic ectodermal dysplasia. This marks the second US location, aiming for 15-20 participants, with the trial also available in Europe. Led by Dr. Ophir Klein, the trial seeks to confirm the safety and efficacy of ER-004, a potential first-of-its-kind medicine for structural birth defects, with all associated expenses covered for participating families.